Skip to main content

Table 2 Comparative statistics of the demographic and laboratory data in p16 gene methylated versus non-methylated HCC patients

From: Aberrant p16 methylation as an early diagnostic marker in blood of hepatocellular carcinoma patients

Parameter

P16 gene non-methylated patients (No. = 4)

P16 gene methylated patients (No. = 26)

H/F*

p value

AST (IU/L)

Median (IQR), range

46 (32.5–53.5), 20–60

68 (49–94), 23–242

21.5

< 0.01*

ALT (IU/L)

Median (IQR), range

42.5 (32.5–67.5), 25–90

40 (26–76), 10–135

30.4

< 0.01*

Total bilirubin (mg/dL)

Median (IQR), range

2.1 (1.15–8.8), 0.6–15.1

2 (1.3–3.4), 0.3–6.2

28.5

< 0.01*

Direct bilirubin (mg/dL)

Median (IQR), range

0.7 (0.5–4.95), 0.4–9.1

0.75 (0.5–1.3), 0.1–2.8

40.5

< 0.01*

Albumin (g/dL)

Mean ± SD, range

3.18 ± 0.76, 2.5–4.1

2.69 ± 0.65 1.5–3.7

64.6*

< 0.01*

INR

Mean ± SD, range

1.17 ± 0.18, 1.03–1.43

1.37 ± 0.24, 1–1.9

33.2*

< 0.01*

AFP (ng/mL)

Mean ± SD, range

5 (2.7–17.25), 1.9–28

131 (14–400), 2.3–3500

28.0

< 0.01*

  1. H: Kruskal-Wallis test, F: ANOVA test
  2. *p < 0.01, highly significant difference